Skip to main content
Funded Studies

Susan Bressman, MD

Chairman, Department of Neurology at Beth Israel Medical Center

Vice Chairman, Department of Neurology at Albert Einstein College of Medicine

Location: New York, NY United States

Susan Bressman is a Director of the American Academy of Neurology, and the President of WE MOVE (Worldwide Education and Awareness of Movement Disorders). WE MOVE is a not for profit dedicated to educating health professionals and the public about movement disorders, neurological conditions that impair motor control including Parkinson’s disease, dystonia, and essential tremor.

Dr. Bressman attended Columbia University’s College of Physicians and Surgeons and received her postgraduate training in neurology at the Columbia Presbyterian Medical Center. After residency she was a Movement Disorders Fellow under Dr. Stanley Fahn and then remained at Columbia where she developed a genetics program in movement disorders and she has continued her clinical genetic research at Beth Israel. Dr. Bressman is recognized for her work identifying genes and characterizing phenotypes; she has been instrumental in the mapping of four and identification of two dystonia genes, as well as PD genotype phenotype studies.

Dr. Bressman is a member of multiple professional organizations and honor societies and serves on the scientific advisory boards and committees of the NIH, Michael J. Fox Foundation for Parkinson’s Research, Bachmann-Strauss Foundation for Dystonia, and Parkinson’s Research, American Academy of Neurology, and the Benign Essential Blepharospasm Research Foundation. Dr. Bressman has lectured in and organized numerous academic courses and symposia, both nationally and internationally. She has more than 120 published articles in peer-reviewed journals, is a co-editor of two books, and has been a named by Castle Connelly, New York Magazine and New York Resident magazine as a Best Doctor.

Associated Grants

  • Registry for the Advancement of Deep Brain Stimulation Therapy in Parkinson's Disease (RAD-PD)


  • Determining Pharmacodynamic Biomarkers of LRRK2 Activity in Lymphocytes


  • Parkinson's Disease, Ashkenazi Jews and LRRK2: a consortium proposal


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.